Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beclin 1 (BECN1) mRNA is the transcript encoding the Beclin 1 protein, a central regulator of macroautophagy and a key member of the Class III phosphatidylinositol 3-kinase (PI3K) complex. This protein acts as a scaffold, coordinating the assembly of various co-factors that initiate autophagosome formation, a process vital for maintaining cellular homeostasis by degrading damaged organelles and misfolded proteins (UniProt Q14457). In clinical contexts, BECN1 is recognized as a potent tumor suppressor; its expression is frequently reduced in breast, ovarian, and prostate cancers, where its loss correlates with increased genomic instability and tumor progression (PubMed: 10619014). In neurodegenerative conditions, such as Alzheimer's disease, BECN1 levels are often diminished, leading to the toxic accumulation of amyloid-beta and tau proteins (PubMed: 16763144). Therapeutic strategies targeting BECN1 mRNA involve the use of RNA interference (RNAi) or antisense oligonucleotides (ASOs) to either silence its expression in specific pathological contexts or, more commonly in research, to investigate the consequences of autophagy inhibition. Emerging mRNA-based therapies also explore the delivery of BECN1 transcripts to restore autophagy in deficient cells, offering a potential avenue for treating proteinopathies and certain malignancies (PubMed: 23392225).
Modulation of Beclin 1 protein expression through RNA interference or antisense-mediated degradation to regulate autophagic flux.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beclin 1 messenger RNA (BECN1 mRNA) (BECN1 mRNA).